Trial · NCT05681715
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 13 (Week 12) | Period 1: RLZ SRD | 100 | percentage of participants | ||
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 13 (Week 12) | Period 1: RLZ MP | 100 | percentage of participants | ||
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 19 (Week 18) | Period 2: RLZ SRD | 100 | percentage of participants | ||
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 19 (Week 18) | Period 2: RLZ MP | 100 | percentage of participants | ||
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26]) | Period 1: RLZ SRD | 35.7 | percentage of participants | ||
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26]) | Period 1: RLZ MP | 29.6 | percentage of participants | ||
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26]) | Period 2: RLZ SRD | 26.9 | percentage of participants | ||
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26]) | Period 2: RLZ MP | 38.5 | percentage of participants | ||
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26]) | RLZ Total | 75.8 | percentage of participants | ||
| Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods | All Participants: Training Period | 0 | percentage of participants | ||
| Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods | Period 1: RLZ SRD | 0 | percentage of participants | ||
| Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods | Period 1: RLZ MP | 0 | percentage of participants | ||
| Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods | Period 2: RLZ SRD | 0 | percentage of participants | ||
| Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods | Period 2: RLZ MP | 0 | percentage of participants | ||
| Percentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study | Period 1: RLZ SRD | 0 | percentage of participants | ||
| Percentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study | Period 1: RLZ MP | 0 | percentage of participants | ||
| Percentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study | Period 2: RLZ SRD | 0 | percentage of participants | ||
| Percentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study | Period 2: RLZ MP | 0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05681715/results